You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 130 No. 7, July 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Radiation Therapy
 •Oncology
 •Head & Neck Cancer
 •Neoplasms of Head & Neck
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic

Intensive Chemoradiotherapy as a Primary Treatment for Organ Preservation in Patients With Advanced Cancer of the Head and Neck

Efficacy, Toxic Effects, and Limitations

Ehab Hanna, MD; Michael Alexiou, MD; Justin Morgan, MD; Jenny Badley, RNP; Anne Marie Maddox, MD; Jose Penagaricano, MD; Chun-Yang Fan, MD, PhD; Randall Breau, MD; James Suen, MD

Arch Otolaryngol Head Neck Surg. 2004;130:861-867.

Objectives  To evaluate the efficacy and toxic effects of intensive chemoradiotherapy as a primary modality for organ preservation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to define the patterns of treatment failure associated with this therapy.

Design  Retrospective review.

Setting  Tertiary care referral center.

Patients  A total of 127 consecutive patients with advanced SCCHN treated with primary concurrent chemoradiotherapy.

Main Outcome Measures  Efficacy data included the rates of tumor response to therapy, organ preservation, disease recurrence, overall and disease-specific survival, and patterns of treatment failure. Toxic effect data included the rate and grade of treatment-related complications and the rate of unscheduled hospital admissions for managing treatment-related toxic effects.

Results  Ninety-six patients (76%) were men and 31 (24%) were women. Average age at diagnosis was 62 years (range, 37-85 years). The primary tumor site was the oropharynx in 58 patients (46%), the larynx in 36 (28%), the hypopharynx in 20 (16%), the oral cavity in 10 (8%), and another site in 3 (2%). Most patients (91%) had stage III or IV disease. Average follow-up was 36 months. Primary chemoradiotherapy achieved complete response at the primary tumor site in 109 patients (86%). Patients with partial response, stable or progressive disease, or recurrence at the primary site underwent salvage surgery. Overall, at mean follow-up of 3 years, local disease control was achieved in 113 patients (89%), and organ preservation was possible in 102 patients (80%). Two thirds of all patients (n = 83) had clinical N+ disease. Complete clinical response to chemoradiotherapy in the neck was achieved in 57 of these patients (69%). However, complete response to chemoradiotherapy was 93%, 62%, and 47% for N1, N2, and N3 disease, respectively (P <.001). Patients achieving less than complete clinical response underwent salvage neck dissection. Overall, at an average follow-up of 36 months, regional disease control was achieved in 76 (92%) of the 83 patients with neck metastasis. Despite this high locoregional control rate, distant metastasis occurred in 18 patients (14%), was the most common site of disease recurrence (53%), and accounted for almost 40% of all treatment failures. Severe (grade 3 or 4) mucositis and neutropenia occurred in 33% and 25% of patients, respectively. Two patients (2%) died of treatment-related toxic effects. At 3-year mean follow-up, disease-specific and overall survival were 72% and 57%, respectively. Most deaths were due to distant metastasis, comorbidity, and second primary tumors.

Conclusions  High rates of locoregional disease control and organ preservation are achievable with primary chemoradiotherapy in patients with advanced SCCHN, but they are associated with severe treatment-related toxic effects. Despite this effective local and regional disease control, improved survival is hampered by the relatively high incidence of distant metastasis, second primary tumors, and comorbidity.


From the Departments of Otolaryngology–Head and Neck Surgery (Drs Hanna, Alexiou, Morgan, Breau, and Suen and Ms Badley), Medical Oncology (Dr Maddox), Radiation Oncology (Dr Penagaricano), and Pathology (Dr Fan), the Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock. Dr Hanna is now with the Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer
Tai et al.
Jpn J Clin Oncol 2008;0:hyn073v1-7.
ABSTRACT | FULL TEXT  

Liver-Directed Surgery for Metastatic Squamous Cell Carcinoma to the Liver: Results of a Multi-Center Analysis
Pawlik et al.
Ann. Surg. Oncol. 2007;14:2807-2816.
ABSTRACT | FULL TEXT  

Multimodal Intensification Regimens for Advanced, Resectable, Previously Untreated Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx: A 12-Year Experience
Schuller et al.
Arch Otolaryngol Head Neck Surg 2007;133:320-326.
ABSTRACT | FULL TEXT  

Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma.
Ozer et al.
Arch Otolaryngol Head Neck Surg 2006;132:385-389.
ABSTRACT | FULL TEXT  

Induction Chemotherapy for Larynx Preservation: Patient Selection or Therapeutic Effect?
Pfister and Ridge
JCO 2006;24:540-543.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.